In Brief: Bayer Cipro
Bayer Cipro: Barr Labs settles ciprofloxacin patent litigation against Bayer on Jan. 16 for $24.6 mil. up front plus a supply agreement to begin in January 1998. Under the supply agreement, Bayer can make payments to Barr or sell Barr ciprofloxacin, presumably at a discounted rate; the monetary value of the supply agreement, which runs through December 2003, is estimated at $25 mil. annually. If Bayer chooses the product option, Barr will market generic ciprofloxicin in conjunction with Rugby, which provided Barr with financial support during the suit. Barr and Rugby also have the unconditional right to begin selling Cipro six months prior to the patent's expiration ("The Pink Sheet" Sept. 9, 1996, T&G-6)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth